The Walter Reed Army Institute of Research (WRAIR) and its component overseas labs, particularly those in Kenya and Thailand, have contributed significantly to vaccine development against malaria and its plasmodium host. 

         WRAIR investigations through the years have provided essential foundational research leading researchers to the most recent experimental study showing that the RTS/S vaccine showed significant protection against the deadly disease. As reported in October 2011 by a frequent WRAIR collaborating organization, GlaxoSmithKline, in Phase III trials, RTS/S reduced the risk of malaria infection by half in African children aged 5 to 17 months